Nuvectis Pharma (NVCT) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 223.1% versus a gain of 3.4%. Nuvectis Pharma is the larger company by market cap ($681.6 million vs $673.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | ZVRA |
|---|---|---|
| Share price | $20.88 | $11.35 |
| Market cap | $681.61M | $673.71M |
| 1-day change | +3.73% | +3.14% |
| YTD return | +166.62% | +22.77% |
| 1-year return | +223.11% | +3.38% |
| 5-year return | — | +12.59% |
| P/E ratio (TTM) | — | 12.33 |
| Forward P/E | — | 10.54 |
| EPS (TTM) | $-1.31 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $15.04 |
| 52-week low | $5.55 | $8.01 |
| Distance from 52-week high | -28.68% | -24.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.54% | +120.36% |
| Average volume | 215.43K | 1.11M |
| Shares outstanding | 32.64M | 59.38M |
| Employees | 16 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed ZVRA by 219.7 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
NVCT vs ZVRA FAQ
Which is bigger, Nuvectis Pharma or Zevra Therapeutics?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $681.61M compared with $673.71M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, NVCT or ZVRA?
NVCT returned +223.11% over the past 12 months, compared with +3.38% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.